cometadata/datacite-titles-descriptions-related-identifiers huggingface dataset:
DOI: 10.6084/m9.figshare.13503004
title: infection-economy-ver2-3.cpp from An agent-based model of the interrelation between the COVID-19 outbreak and economic activities

description: Source code files of the simulation
DOI: 10.6084/m9.figshare.13503004.v1
title: infection-economy-ver2-3.cpp from An agent-based model of the interrelation between the COVID-19 outbreak and economic activities

description: Source code files of the simulation
DOI: 10.6084/m9.figshare.13503016
title: Monitor.cpp from An agent-based model of the interrelation between the COVID-19 outbreak and economic activities

description: Source code files of the simulation
DOI: 10.6084/m9.figshare.13503016.v1
title: Monitor.cpp from An agent-based model of the interrelation between the COVID-19 outbreak and economic activities

description: Source code files of the simulation
DOI: 10.6084/m9.figshare.13502973.v1
title: Data and scripts for Figures 1 to 7 from Using adjoint-based optimization to enhance ignition in non-premixed jets

description: Data and Matlab files to reproduce Figures 1 to 7.
DOI: 10.6084/m9.figshare.13502829
title: lva_uniprot_pfam.tsv

description: Annotation table for reference transcriptome of sponge Leucosolenia cf. variabilis (Calcarea, Porifera) contains result of BLAST and HMMscan searching against SwissProt and Pfam databases, respectively.
DOI: 10.6084/m9.figshare.13502829.v1
title: lva_uniprot_pfam.tsv

description: Annotation table for reference transcriptome of sponge Leucosolenia cf. variabilis (Calcarea, Porifera) contains result of BLAST and HMMscan searching against SwissProt and Pfam databases, respectively.
DOI: 10.15468/pap3ng
title: Two new species of Batriscenellus Jeannel from tropical Asia (Coleoptera Staphylinidae: Pselaphinae)

description: This dataset contains the digitized treatments in Plazi based on the original journal article Yin, Zi-Wei, Kleeberg, Andreas (2020): Two new species of Batriscenellus Jeannel from tropical Asia (Coleoptera Staphylinidae: Pselaphinae). Zootaxa 4822 (1): 121-126, DOI: https://doi.org/10.11646/zootaxa.4822.1.7
DOI: 10.18462/iir.gl.2020.1147
title: Two-fluid CFD model for R744 two-phase ejectors.
DOI: 10.18462/iir.gl.2020.1148
title: Efficiency of a small-scale natural gas liquefier using natural refrigerant pre-cooling driven by Organic Rankine Cycle.
DOI: 10.18462/iir.gl.2020.1150
title: Multipurpose natural mixed refrigerant system for application region of two cascade systems.
DOI: 10.18462/iir.gl.2020.1151
title: Experimental analysis of CO2 blends for transcritical refrigeration systems.
DOI: 10.18462/iir.gl.2020.1152
title: Numerical analysis of flow maldistribution in large-scale liquid overfed finned-tube ammonia evaporators.
DOI: 10.5281/zenodo.4400235
title: Dataset related to article "Morphometric vertebral fractures in patients with castration-resistant prostate cancer undergoing treatment with radium-223: a longitudinal study in the real-life clinical practice"

description: This record contains data related to article "Morphometric vertebral fractures in patients with castration-resistant prostate cancer undergoing treatment with radium-223: a longitudinal study in the real-life clinical practice" <strong>Abstract</strong> <strong>Purpose: </strong>Radium-223 was associated with high incidence of non-vertebral fractures in patients with castration-resistant prostate cancer (CRPC). However, it is still unclear whether radium-223 may induce skeletal fragility regardless of other therapies for CRPC. We aimed at evaluating the prevalence, incidence, and determinants of vertebral fractures (VFs), i.e., the most frequent complication of skeletal fragility, in CRCP patients undergoing radium-223 therapy in the real-life clinical practice. <strong>Methods: </strong>We retrospectively reviewed 49 CRPC patients with symptomatic bone metastases treated with radium-223. Patients received median number of four radium-223 doses (range: 2-6) and were followed-up for a median period of 11 months (range: 6-44). VFs were assessed by a quantitative morphometry using lateral images of spine 11C-Choline PET/CT, excluding from the analysis the vertebral bodies affected by bone metastases. <strong>Results: </strong>Before radium-223 administration, 24 patients (49%) had VFs significantly associated with duration of androgen deprivation therapy (ADT; odds ratio 1.29) and previous abiraterone therapy (odds ratio 3.80). During radium-223 therapy, incident VFs occurred in 25% of patients, in relationship with prevalent VFs (hazard ratio 6.89) and change in serum total alkaline phosphatase values (hazard ratio 0.97), whereas the correlations with ADT and abiraterone therapy were lost. Noteworthy, the risk of VFs did not correlate with the therapeutic end points of radium-223. <strong>Conclusions: </strong>This study provides a first evidence that in real-life clinical practice, radium-223 therapy may induce skeletal fragility with high risk of VFs, likely by inhibition of bone formation and independently of ADT and abiraterone therapy.
DOI: 10.5281/zenodo.4400234
title: Dataset related to article "Morphometric vertebral fractures in patients with castration-resistant prostate cancer undergoing treatment with radium-223: a longitudinal study in the real-life clinical practice"

description: This record contains data related to article "Morphometric vertebral fractures in patients with castration-resistant prostate cancer undergoing treatment with radium-223: a longitudinal study in the real-life clinical practice" <strong>Abstract</strong> <strong>Purpose: </strong>Radium-223 was associated with high incidence of non-vertebral fractures in patients with castration-resistant prostate cancer (CRPC). However, it is still unclear whether radium-223 may induce skeletal fragility regardless of other therapies for CRPC. We aimed at evaluating the prevalence, incidence, and determinants of vertebral fractures (VFs), i.e., the most frequent complication of skeletal fragility, in CRCP patients undergoing radium-223 therapy in the real-life clinical practice. <strong>Methods: </strong>We retrospectively reviewed 49 CRPC patients with symptomatic bone metastases treated with radium-223. Patients received median number of four radium-223 doses (range: 2-6) and were followed-up for a median period of 11 months (range: 6-44). VFs were assessed by a quantitative morphometry using lateral images of spine 11C-Choline PET/CT, excluding from the analysis the vertebral bodies affected by bone metastases. <strong>Results: </strong>Before radium-223 administration, 24 patients (49%) had VFs significantly associated with duration of androgen deprivation therapy (ADT; odds ratio 1.29) and previous abiraterone therapy (odds ratio 3.80). During radium-223 therapy, incident VFs occurred in 25% of patients, in relationship with prevalent VFs (hazard ratio 6.89) and change in serum total alkaline phosphatase values (hazard ratio 0.97), whereas the correlations with ADT and abiraterone therapy were lost. Noteworthy, the risk of VFs did not correlate with the therapeutic end points of radium-223. <strong>Conclusions: </strong>This study provides a first evidence that in real-life clinical practice, radium-223 therapy may induce skeletal fragility with high risk of VFs, likely by inhibition of bone formation and independently of ADT and abiraterone therapy.
DOI: 10.18462/iir.gl.2020.1153
title: Numerical investigation of a CO2 cooling unit for refrigerating transport operating switching between different configurations.
DOI: 10.18462/iir.gl.2020.1155
title: Energy performance of a CO2 transcritical refrigerating plant with a thermoelectric subcooler system.
DOI: 10.18462/iir.gl.2020.1160
title: Experimental and numerical investigation of a transcritical CO2 air/water reversible heat pump: analysis of domestic hot water.
DOI: 10.5519/qd.utyzgdq6
title: Query on the Natural History Museum Data Portal (data.nhm.ac.uk) (234 records)
DOI: 10.18462/iir.gl.2020.1164
title: Zeotropic mixtures in low temperature Rankine cycles.
DOI: 10.5281/zenodo.4400254
title: Dataset related to article "Secondary hyperparathyroidism and thoracic vertebral fractures in heart failure middle-aged patients: a 3-year prospective study"

description: This record contains data related to article "Secondary hyperparathyroidism and thoracic vertebral fractures in heart failure middle-aged patients: a 3-year prospective study" Abstract <strong>Purpose: </strong>Vertebral fractures (VFs) were described in elderly patients with heart failure (HF) whereas their prevalence and determinants in younger HF patients are still unknown. This study aimed at assessing whether secondary hyperparathyroidism (SHPT) may influence the risk of VFs in middle-aged patients with HF. <strong>Methods: </strong>84 patients (44 males, median age 48.5 years, range 43-65) with HF were prospectively evaluated at the baseline and after 36-month follow-up for bone mineral density (BMD) and VFs by quantitative morphometry on chest X-rays. Serum PTH, calcium, 25-hydroxyvitamin D and 24-h-urinary calcium were evaluated at the baseline and every 6-12 months during the study period. <strong>Results: </strong>At baseline, SHPT, hypovitaminosis D and VFs were found in 43 patients (51.2%), 73 patients (86.9%) and 29 patients (34.5%), respectively. SHPT was associated with VFs at baseline [inverse probability-weighted (ipw) odds ratio (OR) 12.2, p &lt; 0.001]. Patients were treated with vitamin D3 alone (56%), vitamin D3 plus calcium carbonate (21.4%), calcitriol alone (4.8%), bisphosphonates plus vitamin D3 (8.3%) or a combination of bisphosphonates, vitamin D3 and calcium carbonate (9.5%). At the end of follow-up, hypovitaminosis D was corrected in all patients, whereas 19/84 patients (22.6%) had persistent SHPT. During the follow-up, 16 patients developed incident VFs which resulted to be associated with baseline SHPT (ipw OR 55.7, p &lt; 0.001), even after adjusting from BMD change from baseline to follow-up (ipw OR 46.4, p &lt; 0.001). <strong>Conclusions: </strong>This study provides a first evidence that SHPT may be a risk factor for VFs in middle-aged patients with HF.
DOI: 10.5281/zenodo.4400253
title: Dataset related to article "Secondary hyperparathyroidism and thoracic vertebral fractures in heart failure middle-aged patients: a 3-year prospective study"

description: This record contains data related to article "Secondary hyperparathyroidism and thoracic vertebral fractures in heart failure middle-aged patients: a 3-year prospective study" Abstract <strong>Purpose: </strong>Vertebral fractures (VFs) were described in elderly patients with heart failure (HF) whereas their prevalence and determinants in younger HF patients are still unknown. This study aimed at assessing whether secondary hyperparathyroidism (SHPT) may influence the risk of VFs in middle-aged patients with HF. <strong>Methods: </strong>84 patients (44 males, median age 48.5 years, range 43-65) with HF were prospectively evaluated at the baseline and after 36-month follow-up for bone mineral density (BMD) and VFs by quantitative morphometry on chest X-rays. Serum PTH, calcium, 25-hydroxyvitamin D and 24-h-urinary calcium were evaluated at the baseline and every 6-12 months during the study period. <strong>Results: </strong>At baseline, SHPT, hypovitaminosis D and VFs were found in 43 patients (51.2%), 73 patients (86.9%) and 29 patients (34.5%), respectively. SHPT was associated with VFs at baseline [inverse probability-weighted (ipw) odds ratio (OR) 12.2, p &lt; 0.001]. Patients were treated with vitamin D3 alone (56%), vitamin D3 plus calcium carbonate (21.4%), calcitriol alone (4.8%), bisphosphonates plus vitamin D3 (8.3%) or a combination of bisphosphonates, vitamin D3 and calcium carbonate (9.5%). At the end of follow-up, hypovitaminosis D was corrected in all patients, whereas 19/84 patients (22.6%) had persistent SHPT. During the follow-up, 16 patients developed incident VFs which resulted to be associated with baseline SHPT (ipw OR 55.7, p &lt; 0.001), even after adjusting from BMD change from baseline to follow-up (ipw OR 46.4, p &lt; 0.001). <strong>Conclusions: </strong>This study provides a first evidence that SHPT may be a risk factor for VFs in middle-aged patients with HF.
DOI: 10.18462/iir.gl.2020.1171
title: Performance evaluation of CO2 HPWH system.
DOI: 10.5517/ccdc.csd.cc230w01
title: CCDC 1937252: Experimental Crystal Structure Determination

description: Related Article: N.S. Kariaka, S.S. Smola, N.V. Rusakova, V.V. Dyakonenko, S.V. Shishkina, T.Yu. Sliva, V.A. Trush, V.M. Amirkhanov|2020|J.Lumin.|223|117187|doi:10.1016/j.jlumin.2020.117187
DOI: 10.5517/ccdc.csd.cc230w12
title: CCDC 1937253: Experimental Crystal Structure Determination

description: Related Article: N.S. Kariaka, S.S. Smola, N.V. Rusakova, V.V. Dyakonenko, S.V. Shishkina, T.Yu. Sliva, V.A. Trush, V.M. Amirkhanov|2020|J.Lumin.|223|117187|doi:10.1016/j.jlumin.2020.117187
DOI: 10.5517/ccdc.csd.cc25tr0s
title: CCDC 2020735: Experimental Crystal Structure Determination

description: Related Article: Marianta Strinoiu, Mihai Răducă, Augustin M. Mădălan|2020|J.Coord.Chem.|73|2786|doi:10.1080/00958972.2020.1830977
DOI: 10.5517/ccdc.csd.cc25tr1t
title: CCDC 2020736: Experimental Crystal Structure Determination

description: Related Article: Marianta Strinoiu, Mihai Răducă, Augustin M. Mădălan|2020|J.Coord.Chem.|73|2786|doi:10.1080/00958972.2020.1830977
DOI: 10.5517/ccdc.csd.cc25tr2v
title: CCDC 2020737: Experimental Crystal Structure Determination

description: Related Article: Marianta Strinoiu, Mihai Răducă, Augustin M. Mădălan|2020|J.Coord.Chem.|73|2786|doi:10.1080/00958972.2020.1830977
DOI: 10.5517/ccdc.csd.cc25tr3w
title: CCDC 2020738: Experimental Crystal Structure Determination

description: Related Article: Marianta Strinoiu, Mihai Răducă, Augustin M. Mădălan|2020|J.Coord.Chem.|73|2786|doi:10.1080/00958972.2020.1830977
DOI: 10.5517/ccdc.csd.cc25tr4x
title: CCDC 2020739: Experimental Crystal Structure Determination

description: Related Article: Marianta Strinoiu, Mihai Răducă, Augustin M. Mădălan|2020|J.Coord.Chem.|73|2786|doi:10.1080/00958972.2020.1830977
DOI: 10.5517/ccdc.csd.cc25tr5y
title: CCDC 2020740: Experimental Crystal Structure Determination

description: Related Article: Marianta Strinoiu, Mihai Răducă, Augustin M. Mădălan|2020|J.Coord.Chem.|73|2786|doi:10.1080/00958972.2020.1830977
DOI: 10.5517/ccdc.csd.cc25tr70
title: CCDC 2020742: Experimental Crystal Structure Determination

description: Related Article: Marianta Strinoiu, Mihai Răducă, Augustin M. Mădălan|2020|J.Coord.Chem.|73|2786|doi:10.1080/00958972.2020.1830977
DOI: 10.18462/iir.gl.2020.1176
title: Assessment of surfactant-induced Marangoni convection within high-temperature aqueous Lithium-Bromide solution.
DOI: 10.5281/zenodo.4400274
title: Dataset related to article "Thyrotoxicosis in patients with COVID-19: the THYRCOV study"

description: This record contains data related to article "Thyrotoxicosis in patients with COVID-19: the THYRCOV study" Abstract <strong>Objective: </strong>This study assessed thyroid function in patients affected by the coronavirus disease-19 (COVID-19), based on the hypothesis that the cytokine storm associated with COVID-19 may influence thyroid function and/or the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) may directly act on thyroid cells, such as previously demonstrated for SARS-CoV-1 infection. <strong>Design and methods: </strong>This single-center study was retrospective and consisted in evaluating thyroid function tests and serum interleukin-6 (IL-6) values in 287 consecutive patients (193 males, median age: 66 years, range: 27-92) hospitalized for COVID-19 in non-intensive care units. <strong>Results: </strong>Fifty-eight patients (20.2%) were found with thyrotoxicosis (overt in 31 cases), 15 (5.2%) with hypothyroidism (overt in only 2 cases), and 214 (74.6%) with normal thyroid function. Serum thyrotropin (TSH) values were inversely correlated with age of patients (rho -0.27; P &lt; 0.001) and IL-6 (rho -0.41; P &lt; 0.001). In the multivariate analysis, thyrotoxicosis resulted to be significantly associated with higher IL-6 (odds ratio: 3.25, 95% confidence interval: 1.97-5.36; P &lt; 0.001), whereas the association with age of patients was lost (P = 0.09). <strong>Conclusions: </strong>This study provides first evidence that COVID-19 may be associated with high risk of thyrotoxicosis in relationship with systemic immune activation induced by the SARS-CoV-2 infection.
DOI: 10.5281/zenodo.4400273
title: Dataset related to article "Thyrotoxicosis in patients with COVID-19: the THYRCOV study"

description: This record contains data related to article "Thyrotoxicosis in patients with COVID-19: the THYRCOV study" Abstract <strong>Objective: </strong>This study assessed thyroid function in patients affected by the coronavirus disease-19 (COVID-19), based on the hypothesis that the cytokine storm associated with COVID-19 may influence thyroid function and/or the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) may directly act on thyroid cells, such as previously demonstrated for SARS-CoV-1 infection. <strong>Design and methods: </strong>This single-center study was retrospective and consisted in evaluating thyroid function tests and serum interleukin-6 (IL-6) values in 287 consecutive patients (193 males, median age: 66 years, range: 27-92) hospitalized for COVID-19 in non-intensive care units. <strong>Results: </strong>Fifty-eight patients (20.2%) were found with thyrotoxicosis (overt in 31 cases), 15 (5.2%) with hypothyroidism (overt in only 2 cases), and 214 (74.6%) with normal thyroid function. Serum thyrotropin (TSH) values were inversely correlated with age of patients (rho -0.27; P &lt; 0.001) and IL-6 (rho -0.41; P &lt; 0.001). In the multivariate analysis, thyrotoxicosis resulted to be significantly associated with higher IL-6 (odds ratio: 3.25, 95% confidence interval: 1.97-5.36; P &lt; 0.001), whereas the association with age of patients was lost (P = 0.09). <strong>Conclusions: </strong>This study provides first evidence that COVID-19 may be associated with high risk of thyrotoxicosis in relationship with systemic immune activation induced by the SARS-CoV-2 infection.
DOI: 10.5281/zenodo.4400291
title: Dataset related to article "TNM 8th edition in thyroid cancer staging: is there an improvement in predicting recurrence?"

description: This record contains data related to article "TNM 8th edition in thyroid cancer staging: is there an improvement in predicting recurrence?" Abstract TNM 8th edition introduces changes in the staging of patients with differentiated thyroid carcinoma (DTC). This study aims at assessing the value of TNM 8th edition in predicting response to therapy and structural recurrence of DTC. Four hundred and eighty DTC patients were retrospectively evaluated by 7th and 8th editions of TNM staging system in relationship with risk stratification, response to therapy and recurrence of disease as defined by 2015 ATA guidelines. As compared to the 7th edition, TNM 8th led to downstage 136 patients (28.3%), with 97.5% of patients falling into lower stages (I-II) and only 2.5% remaining in higher stages (III-IV) (P &lt; 0.001). Patients who were downstaged in stages I-II by TNM 8th were classified more frequently at intermediate-high risk (P &lt; 0.001), had more frequently structural incomplete response to therapy (P = 0.009) and had higher risk of structural recurrence (P = 0.002) as compared to patients who were in the same TNM stages but were not downstaged. Specifically, the risk of structural recurrence was significantly higher in patients in whom the downstaging was induced by changes in tumour classification (hazard ratio (HR) 6.18, 95% CI 2.20-17.40; P = 0.001) but not in those who were downstaged for the increase in age cut-off (HR 2.80, 95% CI 0.86-9.19; P = 0.09). In conclusion, TNM 8th edition did not show reliability in predicting aggressiveness of DTC. In fact, the downstaging of DTC patients especially when performed due to changes in tumour classification may overlook patients predisposed to structural recurrence, potentially causing uncertainty in the therapeutic decision-making at the time of disease's diagnosis.
DOI: 10.5281/zenodo.4400290
title: Dataset related to article "TNM 8th edition in thyroid cancer staging: is there an improvement in predicting recurrence?"

description: This record contains data related to article "TNM 8th edition in thyroid cancer staging: is there an improvement in predicting recurrence?" Abstract TNM 8th edition introduces changes in the staging of patients with differentiated thyroid carcinoma (DTC). This study aims at assessing the value of TNM 8th edition in predicting response to therapy and structural recurrence of DTC. Four hundred and eighty DTC patients were retrospectively evaluated by 7th and 8th editions of TNM staging system in relationship with risk stratification, response to therapy and recurrence of disease as defined by 2015 ATA guidelines. As compared to the 7th edition, TNM 8th led to downstage 136 patients (28.3%), with 97.5% of patients falling into lower stages (I-II) and only 2.5% remaining in higher stages (III-IV) (P &lt; 0.001). Patients who were downstaged in stages I-II by TNM 8th were classified more frequently at intermediate-high risk (P &lt; 0.001), had more frequently structural incomplete response to therapy (P = 0.009) and had higher risk of structural recurrence (P = 0.002) as compared to patients who were in the same TNM stages but were not downstaged. Specifically, the risk of structural recurrence was significantly higher in patients in whom the downstaging was induced by changes in tumour classification (hazard ratio (HR) 6.18, 95% CI 2.20-17.40; P = 0.001) but not in those who were downstaged for the increase in age cut-off (HR 2.80, 95% CI 0.86-9.19; P = 0.09). In conclusion, TNM 8th edition did not show reliability in predicting aggressiveness of DTC. In fact, the downstaging of DTC patients especially when performed due to changes in tumour classification may overlook patients predisposed to structural recurrence, potentially causing uncertainty in the therapeutic decision-making at the time of disease's diagnosis.